POSB118 Cost-Effectiveness of Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets in Acquired Immunodeficiency Syndrome from the Chinese Payer Perspective
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.391
https://www.valueinhealthjournal.com/article/S1098-3015(21)02186-0/fulltext
Title :
POSB118 Cost-Effectiveness of Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets in Acquired Immunodeficiency Syndrome from the Chinese Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02186-0&doi=10.1016/j.jval.2021.11.391
First page :
Section Title :
Open access? :
No
Section Order :
11171